incid
multidrugresist
acinetobact
baumannii
bloodstream
infect
bsi
increas
twoto
fourfold
three
isra
hospit
account
hospitalacquir
bsi
associ
increas
carbapenem
resist
reach
dramat
increas
carbapenem
consumpt
inhospit
fatal
rate
rang
significantli
higher
seen
nosocomi
gramneg
pathogen
baumannii
restrict
intens
care
unit
spread
hospit
ward
multidrugresist
baumannii
potenti
reach
endem
hospit
warrant
vigor
innov
effort
limit
spread
acinetobact
spp
ubiquit
natur
present
virtual
water
soil
sampl
carri
frequent
human
skin
mucou
membran
surviv
extend
period
time
dri
environ
within
acinetobact
genu
least
genom
speci
identifi
given
speci
name
baumannii
genom
speci
close
relat
speci
calcoaceticu
unnam
genom
speci
jointli
refer
calcoaceticusa
baumannii
complex
baumannii
gain
recognit
recent
year
increasingli
preval
nosocomi
pathogen
featur
genu
allow
saprophyt
exist
assist
spread
hospit
name
abil
surviv
inanim
environ
strike
capac
develop
antibiot
resist
baumannii
compris
nosocomi
bloodstream
infect
bsi
us
scope
project
sentri
surveil
preval
acinetobact
spp
among
nosocomi
bacteraemia
rang
canada
latin
america
sourc
blood
rate
higher
spain
rate
describ
israel
sever
hospit
experienc
sharp
rise
preval
baumannii
infect
describ
experi
baumannii
infect
three
hospit
locat
central
israel
studi
hospit
larg
univers
hospit
hospit
hospit
b
hospit
c
bed
gener
intens
care
unit
icu
bed
hospit
hospit
c
hospit
b
number
bed
increas
thereaft
hospit
burn
neurosurgeri
depart
hospit
b
also
perform
solid
organ
transplant
cardiovascular
surgeri
bone
marrow
transplant
perform
hospit
fatal
rate
compris
inhospit
death
caus
hospit
bsi
defin
bsi
occur
h
admiss
data
collect
prospect
hospit
b
patient
chart
review
hospit
c
multipl
isol
within
infecti
episod
count
analysi
nosocomi
baumannii
bsi
incid
express
number
bsi
per
patientday
hospit
carbepenem
consumpt
data
given
defin
daili
dose
ddd
per
patientday
ddd
g
ddd
g
chisquar
test
use
conting
tabl
hospit
blood
cultur
specimen
inocul
bactalert
bottl
organon
teknika
durham
nc
usa
identif
isol
suscept
test
perform
use
standard
bacteriolog
method
includ
autom
system
microscan
baxter
healthcar
corpor
west
sacramento
ca
usa
vitek
ii
system
durham
nc
usa
hospit
b
c
blood
cultur
specimen
inocul
aerob
bottl
anaerob
bottl
process
bactec
microbi
detect
system
becton
dickinson
franklin
lake
nj
usa
suscept
antibiot
test
disc
diffus
agar
method
muellerhinton
agar
accord
nation
committe
clinic
laboratori
standard
procedur
identif
system
use
may
distinguish
close
relat
genotyp
strain
acinetobact
sp
thu
organ
refer
baumannii
may
belong
close
relat
strain
number
baumannii
nosocomi
bsi
occur
hospit
hospit
b
hospit
c
studi
year
incid
nosocomi
baumannii
bsi
increas
substanti
hospit
figur
incid
highest
hospit
c
rise
continu
bsi
per
patientday
hospit
b
incid
rose
episod
per
patientday
declin
thereaft
hospit
incid
lower
increas
twofold
episod
per
patientday
within
three
year
appear
hospit
b
baumannii
becam
singl
common
isol
among
nosocomi
bsi
rate
nosocomi
bsi
tabl
hospit
c
preval
baumannii
among
nosocomi
bsi
rang
respect
hospit
b
baumannii
common
hospitalacquir
gramneg
bsi
baumannii
isol
resist
multipl
antibiot
isol
suscept
amikacin
imipenem
meropenem
ampicillinsulbactam
colistin
overal
isol
resist
amikacin
studi
year
resist
imipenem
increas
progress
hospit
hospit
b
hospit
c
suscept
test
ampicillinsulbactam
perform
hospit
b
twentythre
percent
isol
hospit
isol
hospit
b
resist
ampicillinsulbactam
suscept
colistin
test
hospit
b
c
nearli
isol
suscept
concurr
carbapenem
consumpt
increas
ddd
per
patientday
hospit
b
c
hospit
b
hospit
c
hospit
consumpt
lower
rang
ddd
per
patientday
inhospit
fatal
rate
follow
baumannii
nosocomi
bsi
higher
fatal
rate
follow
nosocomi
bsi
due
pseudomona
aeruginosa
klebsiella
pneumonia
tabl
hospit
major
baumannii
bsi
acquir
outsid
icu
mainli
medic
depart
bsi
incid
howev
highest
icu
hospit
b
bsi
acquir
icu
incid
icuacquir
baumannii
bsi
per
patientday
compar
outsid
icu
data
sourc
bsi
avail
hospit
b
prospect
surveil
pneumonia
account
baumannii
bsi
abdomin
postop
infect
account
catheterrel
infect
account
bsi
associ
urinari
tract
infect
uti
sourc
infect
remain
unknown
patient
fatal
highest
unknown
sourc
infect
pneumonia
respect
lowest
uti
bsi
caus
p
aeruginosa
episod
k
pneumonia
episod
less
commonli
associ
pneumonia
respect
commonli
associ
abdomin
infect
catheterrel
infect
uti
bsi
caus
baumannii
increas
dramat
three
isra
hospit
compris
increasingli
signific
percentag
hospitalacquir
bsi
isol
resist
cephalosporin
increasingli
resist
carbapenem
fatal
rate
consist
higher
seen
notori
lifethreaten
gramneg
infect
hospit
interestingli
infect
limit
icu
acquir
multipl
locat
hospit
mainli
medic
depart
result
studi
major
concern
sinc
preval
resist
rate
baumannii
isra
centr
higher
report
locat
report
usa
austria
describ
resist
imipenem
bloodstream
isol
latin
america
bloodstream
isol
resist
imipenem
resist
preval
spain
reach
comparison
resist
rate
imipenem
last
year
studi
crude
mortal
rate
similar
describ
studi
report
previous
israel
scope
project
patient
baumannii
bsi
die
compar
bsi
provoc
match
cohort
studi
claim
baumannii
bsi
associ
increas
mortal
rate
critic
ill
patient
studi
crude
mortal
acinetobact
case
vs
among
control
possibl
high
mortal
rate
studi
explain
sever
underli
diseas
patient
popul
anoth
possibl
explan
associ
pneumonia
sourc
infect
two
four
time
frequent
baumannii
compar
gramneg
nosocomi
pathogen
assess
appropri
empir
antibiot
treatment
clonal
virul
spread
baumannii
almost
hospit
depart
within
year
describ
studi
anoth
caus
major
concern
potenti
baumannii
persist
environ
spread
effect
among
patient
defeat
tradit
infect
control
measur
hospit
infect
control
measur
implement
baumannii
infect
point
environment
clean
import
control
acinetobact
outbreak
howev
success
report
describ
small
outbreak
control
measur
implement
small
unit
report
find
highlight
potenti
multidrugresist
baumannii
establish
endem
hospit
similar
recent
sever
acut
respiratori
syndrom
sar
outbreak
anoth
alert
possibl
emerg
new
pathogen
unpreced
abil
spread
hospit
increas
alreadi
high
burden
nosocomi
infect
